RxDoctor Payments Data

Laura Lucio Reincke, MD

Family Medicine · Saint Clair, MINPI 1851392930

Payments from drug & device makers

$1,485in general payments, 2019–2025

Across 26 payments — averaging $57.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$610
  • Takeda Pharmaceuticals U.S.A., Inc.$195
  • AbbVie$147
  • Phathom Pharmaceuticals, Inc.$125
  • Pfizer$113
  • Lilly USA, LLC$103
  • plus $193 from 3 others

What the payments were for

  • Food & beverage$1,32089%
  • Education$16511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,485 in reported general payments places this provider in the 75th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$68,123
Medicare patients
182
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$97,900
MounjaroTirzepatide55$85,587
JardianceEmpagliflozin40$41,501
EliquisApixaban37$32,552
RybelsusSemaglutide12$23,722
Levothyroxine Sodium355$5,408
Atorvastatin Calcium343$4,511
Rosuvastatin Calcium233$4,123
Qvar RedihalerBeclomethasone Dipropionate17$3,977
Metoprolol Succinate154$2,757
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,661
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril81$2,316
Albuterol Sulfate HfaAlbuterol Sulfate47$2,019
Fentanyl14$1,828
Omeprazole137$1,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$610$121,62389 claims
Lilly USA, LLCMounjaro$103$85,58755 claims
Boehringer IngelheimJardiance$15$41,50140 claims
PfizerEliquis$113$32,55237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Saint Clair

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →